Early prediction of pathological complete response in luminal B type neoadjuvant chemotherapy-treated breast cancer patients: comparison between interim F-18-FDG PET/CT and MRI
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pahk, Kisoo | - |
dc.contributor.author | Kim, Sungeun | - |
dc.contributor.author | Choe, Jae Gol | - |
dc.date.accessioned | 2021-09-04T13:01:55Z | - |
dc.date.available | 2021-09-04T13:01:55Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2015-09 | - |
dc.identifier.issn | 0143-3636 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/92588 | - |
dc.description.abstract | PurposeThe aim of this study is to justify the effectiveness of interim PET/computed tomography (CT) for predicting pathological complete response (pCR) in luminal B type breast cancer patients and to compare the diagnostic performance of interim PET/CT and MRI.Materials and methodsTwenty-one patients with neoadjuvant chemotherapy (NAC)-treated luminal B type breast cancer were included. All patients underwent PET/CT and MRI at baseline and interim (mid-point). Breast surgery was performed after completion of NAC. Maximum standardized uptake values (SUVmax) of breast malignant lesions in each PET/CT scan were acquired in each patient. The metabolic response was calculated as follows: SUV (%)=(baseline SUVmax-interim SUVmax)/baseline SUV(max)x100 (%). In MRI, the relative size change was calculated as follows: Size change (%)=longest diameter interim MRI-longest diameter baseline MRI/longest diameter baseline MRIx100 (%). pCR was concluded through the final pathologic specimen after breast surgery. The receiver-operating characteristic analysis was used as a statistical method.ResultsOf 21 patients, seven achieved a pCR after surgery. In PET/CT, an optimal cut-off SUV (%) of 69.0% was proposed with a sensitivity of 85.7% and a specificity of 100% (P<0.0001). In MRI, an optimal cut-off size change (%) was 38.2% with a sensitivity of 64.3% and a specificity of 71.4% (P=0.29). The area under the curve was 0.92 and 0.65, respectively. PET/CT presented better predictability of the pCR than MRI (P=0.04).ConclusionIn luminal B type NAC-treated breast cancer patients, it is possible to use PET/CT as an early surrogate marker for predicting pCR and it is significantly more predictable for pCR than MRI. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.subject | PREOPERATIVE CHEMOTHERAPY | - |
dc.subject | RESIDUAL TUMOR | - |
dc.subject | SURVIVAL | - |
dc.title | Early prediction of pathological complete response in luminal B type neoadjuvant chemotherapy-treated breast cancer patients: comparison between interim F-18-FDG PET/CT and MRI | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Sungeun | - |
dc.contributor.affiliatedAuthor | Choe, Jae Gol | - |
dc.identifier.doi | 10.1097/MNM.0000000000000329 | - |
dc.identifier.scopusid | 2-s2.0-84938778842 | - |
dc.identifier.wosid | 000359854400004 | - |
dc.identifier.bibliographicCitation | NUCLEAR MEDICINE COMMUNICATIONS, v.36, no.9, pp.887 - 891 | - |
dc.relation.isPartOf | NUCLEAR MEDICINE COMMUNICATIONS | - |
dc.citation.title | NUCLEAR MEDICINE COMMUNICATIONS | - |
dc.citation.volume | 36 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 887 | - |
dc.citation.endPage | 891 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Radiology, Nuclear Medicine & Medical Imaging | - |
dc.relation.journalWebOfScienceCategory | Radiology, Nuclear Medicine & Medical Imaging | - |
dc.subject.keywordPlus | PREOPERATIVE CHEMOTHERAPY | - |
dc.subject.keywordPlus | RESIDUAL TUMOR | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordAuthor | breast cancer | - |
dc.subject.keywordAuthor | F-18-FDG PET | - |
dc.subject.keywordAuthor | luminal B type | - |
dc.subject.keywordAuthor | MRI | - |
dc.subject.keywordAuthor | neoadjuvant chemotherapy | - |
dc.subject.keywordAuthor | PET/CT | - |
dc.subject.keywordAuthor | response | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.